Comments

TScan Therapeutics

TCRXNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$7.35
-0.14-1.87%
At Close: -
$7.35
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
TScan Therapeutics (TCRX) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$22.00
Lowest Price Target1
$9.00
Consensus Price Target1
$14.29

want to know what
the Bulls & Bears Say?

TScan Therapeutics (NASDAQ:TCRX) Stock, Analyst Ratings, Price Targets, Forecasts

TScan Therapeutics Inc has a consensus price target of $14.29 based on the ratings of 8 analysts. The high is $22 issued by Morgan Stanley on August 10, 2021. The low is $9 issued by Barclays on March 7, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BTIG, and HC Wainwright & Co. on June 4, 2024, May 16, 2024, and May 14, 2024, respectively. With an average price target of $14 between HC Wainwright & Co., BTIG, and HC Wainwright & Co., there's an implied 90.48% upside for TScan Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
1
Mar
1
Apr
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
BTIG
Needham
Wedbush
Barclays

1calculated from analyst ratings

Analyst Ratings for TScan Therapeutics

Buy NowGet Alert
06/04/2024Buy Now104.08%HC Wainwright & Co.
Andrew Fein
$15 → $15ReiteratesBuy → BuyGet Alert
05/16/2024Buy Now63.27%BTIG
Justin Zelin
 → $12Initiates → BuyGet Alert
05/14/2024Buy Now104.08%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
05/13/2024Buy Now49.66%Needham
Gil Blum
 → $11ReiteratesBuy → BuyGet Alert
04/23/2024Buy Now36.05%Wedbush
David Nierengarten
 → $10ReiteratesOutperform → OutperformGet Alert
03/07/2024Buy Now22.45%Barclays
Peter Lawson
$7 → $9MaintainsOverweightGet Alert
03/07/2024Buy Now104.08%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
02/01/2024Buy Now22.45%Wedbush
David Nierengarten
 → $9ReiteratesOutperform → OutperformGet Alert
08/14/2023Buy Now104.08%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
06/22/2023Buy Now8.84%Wedbush
David Nierengarten
 → $8Initiates → OutperformGet Alert
05/18/2023Buy Now104.08%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now104.08%HC Wainwright & Co.
Andrew Fein
 → $15ReiteratesBuy → BuyGet Alert
03/09/2023Buy Now104.08%HC Wainwright & Co.
Andrew Fein
 → $15Reiterates → BuyGet Alert
05/10/2022Buy Now104.08%HC Wainwright & Co.
Andrew Fein
$21 → $15MaintainsBuyGet Alert
12/16/2021Buy Now185.71%HC Wainwright & Co.
Andrew Fein
—Initiates → BuyGet Alert
08/13/2021Buy Now—Cowen & Co.
Boris Peaker
—Initiates → OutperformGet Alert
08/10/2021Buy Now199.32%Morgan Stanley
Vikram Purohit
—Initiates → OverweightGet Alert
08/10/2021Buy Now185.71%Jefferies
Chris Howerton
—Initiates → BuyGet Alert

FAQ

Q

What is the target price for TScan Therapeutics (TCRX) stock?

A

The latest price target for TScan Therapeutics (NASDAQ:TCRX) was reported by HC Wainwright & Co. on June 4, 2024. The analyst firm set a price target for $15.00 expecting TCRX to rise to within 12 months (a possible 104.08% upside). 9 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for TScan Therapeutics (TCRX)?

A

The latest analyst rating for TScan Therapeutics (NASDAQ:TCRX) was provided by HC Wainwright & Co., and TScan Therapeutics reiterated their buy rating.

Q

When was the last upgrade for TScan Therapeutics (TCRX)?

A

There is no last upgrade for TScan Therapeutics

Q

When was the last downgrade for TScan Therapeutics (TCRX)?

A

There is no last downgrade for TScan Therapeutics.

Q

When is the next analyst rating going to be posted or updated for TScan Therapeutics (TCRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TScan Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TScan Therapeutics was filed on June 4, 2024 so you should expect the next rating to be made available sometime around June 4, 2025.

Q

Is the Analyst Rating TScan Therapeutics (TCRX) correct?

A

While ratings are subjective and will change, the latest TScan Therapeutics (TCRX) rating was a reiterated with a price target of $15.00 to $15.00. The current price TScan Therapeutics (TCRX) is trading at is $7.35, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch